DRMA and DRMAW Related Headlines
Go Back- Dermata gets Australian patent acceptance for dermal filler delivery system
- Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
- Dermata appoints Kyra Peckaitis as VP of marketing for Tome skincare launch
- Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
- Dermata Opens a New Chapter with the Release of Tome Skincare
- Dermata receives Australian patent for Spongilla acne treatment technology
- Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
- Dermata Therapeutics closes $12.4 million private placement
- Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Dermata Therapeutics raises $4.1 million in private placement
- Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
- Dermata receives Australian patent acceptance for acne treatment
- Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
- Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
- Dermata Therapeutics shifts focus to over-the-counter skin products
- Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
- Dermata (DRMA) receives Australian patent for topical botulinum toxin treatment
- Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
DRMA and DRMAW Related Press Releases
Go Back- Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
- Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
- Dermata Opens a New Chapter with the Release of Tome Skincare
- Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
- Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
- Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
- Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
- Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
- Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
